TOCTINO CAPSULE

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

ALITRETINOIN

제공처:

GLAXOSMITHKLINE INC

ATC 코드:

D11AH04

INN (International Name):

ALITRETINOIN

복용량:

30MG

약제 형태:

CAPSULE

구성:

ALITRETINOIN 30MG

관리 경로:

ORAL

패키지 단위:

30

처방전 유형:

Prescription

치료 영역:

MISC. SKIN AND MUCOUS MEMBRANE AGENTS

제품 요약:

Active ingredient group (AIG) number: 0137581003; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2023-07-14

제품 특성 요약

_1343/521 TOCTINO _
_ _
_Page 1 of 43_
PRODUCT MONOGRAPH
PR
TOCTINO
alitretinoin
Soft capsule 10 mg and 30 mg
Immunomodulator/Anti-inflammatory
agent
GlaxoSmithKline
Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Submission
Control No. : 225922
Date of Revision:
June 25, 2019
_©_
_ 2019 GSK group of companies or its licensor_
_Trademarks are owned by or licensed to the GSK group of companies. _
_1343/521 TOCTINO _
_ _
_Page 2 of 43_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................. 3
INDICATIONS AND CLINICAL USE
.......................................................................
3
CONTRAINDICATIONS
.........................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................
5
ADVERSE REACTIONS
.......................................................................................
13
DRUG INTERACTIONS
........................................................................................
17
DOSAGE AND ADMINISTRATION
......................................................................
19
OVERDOSAGE
....................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 21
STORAGE AND STABILITY
.................................................................................
24
SPECIAL HANDLING INSTRUCTIONS
................................................................. 24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 24
PART II: SCIENTIFIC
INFORMATION.......................................................................
25
PHARMACEUTICAL INFORMATION
................................................................... 25
CLINICAL TRIALS
...................................